Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer

Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [2,3]). It has recently been determined that the chemotherapy-response signatures in [2] are not reproducible, causing retraction of that article [3]. As such, the results presented in Figure 4 of our original paper [1] are no longer valid. We believe that the data presented in Figures 1-3 of our article remain valid. However, as Figure 4 can no longer be considered valid, portions of [1] are no longer applicable, including the Materials and Methods section entitled " Chemosensitivity signatures " , the Results section entitled " Genomic signatures that predict response to cytotoxic chemotherapeutics " , and other statements in the Abstract, Introduction, Results, Discussion, and Conclusions sections that refer directly or indirectly to the integration of chemotherapy-response signatures into the analytical approach presented in the manuscript. As such, the focus of the manuscript on the utility of an integrated approach using three complementary strate gies for gene expression analysis (i.e. breast cancer intrinsic subtype analysis, pathway prediction and chemo therapy-response signatures) should now be interpreted as referring exclusively to the integration of two comple-men tary strategies. Competing interests The authors declare that they have no competing interests. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.